Hemostatic efficacy 12 hours after the end of infusion: excellent 171/249, good 33/249, poor 45/249; percent change from baseline in anti-FXa activity after andexanet treatment (95% CI) at end of bolus: apixaban group: -92% (-93 to -91) rivaroxaban group: -92% (-94 to -88) enoxaparin group: -75% (-79 to -66); mortality within 30 days 49/352; thrombotic events within 30 days 34/352 MI 7, stroke 14, TIA 1, DVT 13, PE 5; a restart of any anticoagulation 220/352. Here, F10 is linked to stroke disorder.